Related references
Note: Only part of the references are listed.The loss of inhibitory C-terminal conformations in disease associated P123H β-synuclein
Maria K. Janowska et al.
PROTEIN SCIENCE (2016)
A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein
Natalie Landeck et al.
MOLECULAR NEURODEGENERATION (2016)
Structural disorder of monomeric α-synuclein persists in mammalian cells
Francois-Xavier Theillet et al.
NATURE (2016)
Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson's disease
Mohamed-Bilal Fares et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy
Fares Bassil et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Cellular GFP Toxicity and Immunogenicity: Potential Confounders in in Vivo Cell Tracking Experiments
Amir Mehdi Ansari et al.
STEM CELL REVIEWS AND REPORTS (2016)
Cellular GFP Toxicity and Immunogenicity: Potential Confounders in in Vivo Cell Tracking Experiments
Amir Mehdi Ansari et al.
STEM CELL REVIEWS AND REPORTS (2016)
Ser129 phosphorylation of endogenous α-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function
Kerstin Buck et al.
NEUROBIOLOGY OF DISEASE (2015)
β-Synuclein Aggregates and Induces Neurodegeneration in Dopaminergic Neurons
Grit Taschenberger et al.
ANNALS OF NEUROLOGY (2013)
Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo
Abid Oueslati et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons
Grit Taschenberger et al.
ACTA NEUROPATHOLOGICA (2012)
A Rationally Designed Six-Residue Swap Generates Comparability in the Aggregation Behavior of α-Synuclein and β-Synuclein
Cintia Roodveldt et al.
BIOCHEMISTRY (2012)
Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons
Ayse Ulusoy et al.
NEUROBIOLOGY OF DISEASE (2012)
Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice
Kelvin C. Luk et al.
SCIENCE (2012)
Distinct mechanisms of axonal globule formation in mice expressing human wild type α-synuclein or dementia with Lewy bodies-linked P123H β-synuclein
Akio Sekigawa et al.
MOLECULAR BRAIN (2012)
被撤回的出版物: Effect of Ser-129 Phosphorylation on Interaction of α-Synuclein with Synaptic and Cellular Membranes (Retracted article. See vol. 295, pg. 13695, 2020)
Naomi P. Visanji et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Authentically Phosphorylated α-Synuclein at Ser129 Accelerates Neurodegeneration in a Rat Model of Familial Parkinson's Disease
Hiroyasu Sato et al.
JOURNAL OF NEUROSCIENCE (2011)
The A53T Mutation is Key in Defining the Differences in the Aggregation Kinetics of Human and Mouse α-Synuclein
Lijuan Kang et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2011)
Neuropathology in Mice Expressing Mouse Alpha-Synuclein
Claus Rieker et al.
PLOS ONE (2011)
Improved Immunodetection of Endogenous α-Synuclein
Byung Rho Lee et al.
PLOS ONE (2011)
Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology
Ayse Ulusoy et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2010)
Human β-Synuclein Rendered Fibrillogenic by Designed Mutations
Shahin Zibaee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Inhibiting α-Synuclein Oligomerization by Stable Cell-Penetrating β-Synuclein Fragments Recovers Phenotype of Parkinson's Disease Model Flies
Ronit Shaltiel-Karyo et al.
PLOS ONE (2010)
A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain
Masayo Fujita et al.
NATURE COMMUNICATIONS (2010)
Dose Optimization for Long-term rAAV-mediated RNA Interference in the Nigrostriatal Projection Neurons
Ayse Ulusoy et al.
MOLECULAR THERAPY (2009)
Species differences between human and rat in the substrate specificity of cathepsin K
Sachiyo Tada et al.
JOURNAL OF BIOCHEMISTRY (2008)
α-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae
James H. Soper et al.
MOLECULAR BIOLOGY OF THE CELL (2008)
Molecular determinants of the aggregation behavior of α- and β-synuclein
Robert C. Rivers et al.
PROTEIN SCIENCE (2008)
Sequence determinants for amyloid fibrillogenesis of human α-synuclein
Shahin Zibaee et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Structural characterization of the intrinsically unfolded protein β-synuclein, a natural negative regulator of α-synuclein aggregation
Carlos W. Bertoncini et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Dynamics of α-synuclein aggregation and inhibition of pore-like oligomer development by β-synuclein
Igor F. Tsigelny et al.
FEBS JOURNAL (2007)
β-synuclein modulates α-synuclein neurotoxicity by reducing α-synuclein protein expression
Yuxin Fan et al.
HUMAN MOLECULAR GENETICS (2006)
Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease
John P. Anderson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
α-synuclein cooperates with CSPα in preventing neurodegeneration
S Chandra et al.
CELL (2005)
Forcing nonamyloidogenic β-synuclein to fibrillate
G Yamin et al.
BIOCHEMISTRY (2005)
Aggregation promoting C-terminal truncation of α-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations
WX Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
β-Synuclein gene alterations in dementia with Lewy bodies
H Ohtake et al.
NEUROLOGY (2004)
Stabilization of α-synuclein protein with aging and familial Parkinson's disease-linked A53T mutation
WX Li et al.
JOURNAL OF NEUROSCIENCE (2004)
An antiaggregation gene therapy strategy for Lewy body disease utilizing β-synuclein lentivirus in a transgenic model
M Hashimoto et al.
GENE THERAPY (2004)
β-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation -: Cross-talk with α-synuclein and implication for Parkinson's disease
CA da Costa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human α-synuclein
HN Du et al.
BIOCHEMISTRY (2003)
β-synuclein inhibits formation of α-synuclein protofibrils:: A possible therapeutic strategy against Parkinson's disease
JY Park et al.
BIOCHEMISTRY (2003)
α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease
C Lo Bianco et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Biophysical properties of the synucleins and their propensities to fibrillate -: Inhibition of α-synuclein assembly by β- and γ-synucleins
VN Uversky et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Prominent perikaryal expression of α- and β-synuclein in neurons of dorsal root ganglion and in medullary neurons
BI Giasson et al.
EXPERIMENTAL NEUROLOGY (2001)
β-synuclein inhibits α-synuclein aggregation:: A possible role as an anti-parkinsonian factor
M Hashimoto et al.
NEURON (2001)
Parkinson's disease-associated α-sylnuclein is more fibrillogenic than β- and γ-synuclein and cannot cross-seed its homologs
AL Biere et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse α-synuclein
JC Rochet et al.
BIOCHEMISTRY (2000)
Share Paper
